DK1784177T3 - Formulering til L-tryptophan omfattende Carbidopa/Benserazid - Google Patents

Formulering til L-tryptophan omfattende Carbidopa/Benserazid

Info

Publication number
DK1784177T3
DK1784177T3 DK05774433T DK05774433T DK1784177T3 DK 1784177 T3 DK1784177 T3 DK 1784177T3 DK 05774433 T DK05774433 T DK 05774433T DK 05774433 T DK05774433 T DK 05774433T DK 1784177 T3 DK1784177 T3 DK 1784177T3
Authority
DK
Denmark
Prior art keywords
tryptophan
formulation
benserazide
carbidopa
present
Prior art date
Application number
DK05774433T
Other languages
English (en)
Inventor
Joachim Dr Kamprad
Original Assignee
Kamprad Kg Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamprad Kg Dr filed Critical Kamprad Kg Dr
Application granted granted Critical
Publication of DK1784177T3 publication Critical patent/DK1784177T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK05774433T 2004-08-12 2005-08-12 Formulering til L-tryptophan omfattende Carbidopa/Benserazid DK1784177T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004039196A DE102004039196B4 (de) 2004-08-12 2004-08-12 Neue Formulierung für L-Tryptophan
PCT/DE2005/001428 WO2006015590A2 (de) 2004-08-12 2005-08-12 Formulierung für l-tryptophan mit carbidopa / benserazid

Publications (1)

Publication Number Publication Date
DK1784177T3 true DK1784177T3 (da) 2009-08-24

Family

ID=35276634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05774433T DK1784177T3 (da) 2004-08-12 2005-08-12 Formulering til L-tryptophan omfattende Carbidopa/Benserazid

Country Status (14)

Country Link
US (1) US8642639B2 (da)
EP (1) EP1784177B1 (da)
JP (1) JP2008509170A (da)
KR (1) KR101239379B1 (da)
CN (1) CN101022795B (da)
AT (1) ATE429912T1 (da)
AU (1) AU2005270573B2 (da)
BR (1) BRPI0514217A (da)
CA (1) CA2576385C (da)
DE (2) DE102004039196B4 (da)
DK (1) DK1784177T3 (da)
RU (1) RU2377983C2 (da)
WO (1) WO2006015590A2 (da)
ZA (1) ZA200700395B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004039196B4 (de) * 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
JP6067292B2 (ja) * 2012-03-19 2017-01-25 サッポロビール株式会社 セロトニン分泌促進剤
US9895353B2 (en) 2013-09-11 2018-02-20 Zzeemag Inc. Use of L-tryptophan for the treatment of parasomnias
LT3193917T (lt) * 2014-09-17 2021-11-25 Io Biotech Aps Vakcinų kompozicijos, apimančios triptofan-2,3-dioksigenazę arba jos fragmentus
CA3007768A1 (en) * 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
GB201521541D0 (en) * 2015-12-07 2016-01-20 Proximagen Ltd New therapeutic uses of enzyme inhibitors
DE102022103658A1 (de) * 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
US5188840A (en) 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
DE3642668A1 (de) * 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
FR2647345B1 (fr) * 1989-05-25 1992-08-28 Trouillas Paul Association de l-5-hydroxy-tryptophane et de benserazide a titre de composition pharmaceutique, notamment utile dans le traitement des troubles de l'equilibre et l'ataxie, cerebelleux ou autres, de toutes origines, et son utilisation pour la preparation de ladite composition
FR2654931B1 (fr) * 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
JP5408684B2 (ja) 1998-10-09 2014-02-05 ゼネラル ミルズ インコーポレイテッド 非連続な保存安定粒子を得るためにマトリックスに感受性液体成分を封入する方法
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
DE102004039196B4 (de) * 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan

Also Published As

Publication number Publication date
EP1784177B1 (de) 2009-04-29
US20110288145A1 (en) 2011-11-24
KR20070048777A (ko) 2007-05-09
CN101022795B (zh) 2012-02-15
DE102004039196B4 (de) 2008-07-31
WO2006015590A2 (de) 2006-02-16
DE502005007201D1 (de) 2009-06-10
CA2576385C (en) 2016-01-05
AU2005270573B2 (en) 2011-03-31
DE102004039196A1 (de) 2006-03-02
AU2005270573A1 (en) 2006-02-16
KR101239379B1 (ko) 2013-03-05
JP2008509170A (ja) 2008-03-27
BRPI0514217A (pt) 2008-06-03
WO2006015590A3 (de) 2006-05-26
RU2377983C2 (ru) 2010-01-10
US8642639B2 (en) 2014-02-04
CN101022795A (zh) 2007-08-22
ATE429912T1 (de) 2009-05-15
ZA200700395B (en) 2008-04-30
RU2007103773A (ru) 2008-09-20
EP1784177A2 (de) 2007-05-16
CA2576385A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
DK1784177T3 (da) Formulering til L-tryptophan omfattende Carbidopa/Benserazid
DK1611088T3 (da) Hydroxymater som terapeutiske midler
GB2427405A (en) Novel hydroxamates as therapeutic agents
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
WO2003066579A3 (en) Novel bicyclic hydroxamates as inhibitors of histone deacetylase
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
TW200621765A (en) Substituted phenylaminothiazoles and their use
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
CY1107204T1 (el) Πιπεραζινοβενζοθειαζολια ως ουσιες για την θεραπευτικη αντιμετωπιση εγκεφαλικων ισχαιμικων διαταραχων ή διαταραχων του κνς
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
DK1670489T3 (da) Brug af xenon med hypotermi til behandling af neonatal asfyksi
EA200600600A1 (ru) Применение агомелатина для приготовления лекарственных средств, предназначенных для лечения маниакально-депрессивных расстройств
AU2003235454A1 (en) Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
DE60322577D1 (de) Tablette enthaltend efletirizin und pseudoephedrin
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний
TW200626129A (en) Combinations of N-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors
TW200512193A (en) Pyridinyl carbamates